Royal Bank Of Canada Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock

Exelixis (NASDAQ:EXEL) had its price objective increased by equities research analysts at Royal Bank Of Canada from $45.00 to $46.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a “sector perform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s price target would indicate a potential upside of 7.73% from the company’s current price.

Several other analysts have also issued reports on the stock. Bank of America lowered shares of Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 price target on the stock. in a research report on Monday, January 5th. Oppenheimer reaffirmed a “market perform” rating and issued a $36.00 target price on shares of Exelixis in a report on Wednesday, November 5th. Wall Street Zen upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. TD Cowen reissued a “buy” rating on shares of Exelixis in a report on Wednesday, November 5th. Finally, Guggenheim lowered Exelixis from a “buy” rating to a “neutral” rating in a research note on Monday, November 3rd. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $47.11.

Exelixis Price Performance

Exelixis stock opened at $42.70 on Wednesday. The stock’s fifty day moving average price is $43.63 and its two-hundred day moving average price is $40.95. Exelixis has a one year low of $32.38 and a one year high of $49.62. The firm has a market cap of $11.09 billion, a PE ratio of 15.42, a price-to-earnings-growth ratio of 0.73 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.20. The firm had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The company’s revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.55 EPS. Sell-side analysts expect that Exelixis will post 2.04 earnings per share for the current fiscal year.

Insider Transactions at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 34,187 shares of the stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $41.88, for a total value of $1,431,751.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 72,230 shares of company stock valued at $3,046,923. 2.82% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in EXEL. Police & Firemen s Retirement System of New Jersey boosted its position in Exelixis by 0.3% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 102,581 shares of the biotechnology company’s stock worth $4,521,000 after buying an additional 274 shares during the period. Richardson Financial Services Inc. raised its stake in shares of Exelixis by 95.1% during the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 292 shares during the last quarter. RHS Financial LLC raised its stake in shares of Exelixis by 2.4% during the fourth quarter. RHS Financial LLC now owns 12,619 shares of the biotechnology company’s stock valued at $553,000 after acquiring an additional 293 shares during the last quarter. Meeder Advisory Services Inc. lifted its holdings in shares of Exelixis by 5.8% during the fourth quarter. Meeder Advisory Services Inc. now owns 5,406 shares of the biotechnology company’s stock worth $237,000 after purchasing an additional 298 shares during the period. Finally, Cim LLC grew its stake in shares of Exelixis by 0.9% in the third quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock worth $1,462,000 after purchasing an additional 305 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

More Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q4 EPS beat and shareholder returns — Exelixis reported $0.94 EPS vs. ~$0.74 consensus and repurchased $264.5M of stock, improving profitability metrics and returning capital to shareholders. Exelixis Reports Solid Earnings
• Positive Sentiment: Zanzalintinib upside — Management is positioning for a potential 2026 launch (PDUFA Dec. 3, 2026) for zanzalintinib in colorectal cancer, which the company cites as a multi‑billion dollar peak-sales opportunity and core to its franchise growth thesis. Pipeline & Franchise Strategy
• Positive Sentiment: Analyst upward moves — Royal Bank of Canada nudged its price target to $46 (sector perform), and Barclays has also raised targets recently, signaling some analyst confidence in the growth story. Analyst Note
• Neutral Sentiment: Core revenue driver — Cabometyx remains the primary revenue engine (franchise sales cited at ~$2.12B) and management guided 2026 revenue to $2.52–2.62B excluding potential zanzalintinib sales. Growth Strategy
• Neutral Sentiment: Supporting disclosure — Full earnings call transcript, presentation and analyst writeups are available for deeper due diligence. Earnings Presentation Call Transcript
• Neutral Sentiment: Short-interest data appears anomalous (reports showing 0 shares); treat as unreliable until corrected by exchanges/clearing agents.
• Negative Sentiment: Revenue miss and conservative baseline guidance — Q4 revenue ($598.7M) came in below the ~$609M consensus and 2026 guidance excludes potential zanzalintinib revenue, creating near‑term uncertainty and prompting profit-taking. Zacks Earnings Coverage
• Negative Sentiment: Mixed analyst stance — Wells Fargo raised its target to $35 but maintains an Equal Weight stance, which implies limited near‑term upside and contrasts with higher targets from other shops; this divergence contributes to volatile near-term sentiment. Wells Fargo Note

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.